BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 26826480)

  • 41. Thyroglobulin measurement in fine-needle aspirate washouts: the criteria for neck node dissection for patients with thyroid cancer.
    Kim MJ; Kim EK; Kim BM; Kwak JY; Lee EJ; Park CS; Cheong WY; Nam KH
    Clin Endocrinol (Oxf); 2009 Jan; 70(1):145-51. PubMed ID: 18466347
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Postradioiodine treatment whole-body scan in the era of 18-fluorodeoxyglucose positron emission tomography for differentiated thyroid carcinoma with elevated serum thyroglobulin levels.
    Leboulleux S; El Bez I; Borget I; Elleuch M; Déandreis D; Al Ghuzlan A; Chougnet C; Bidault F; Mirghani H; Lumbroso J; Hartl D; Baudin E; Schlumberger M
    Thyroid; 2012 Aug; 22(8):832-8. PubMed ID: 22853728
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Role of [(18)F]-fluorodeoxy-D-glucose positron emission tomography and computed tomography in the early detection of persistent/recurrent thyroid carcinoma in intermediate-to-high risk patients following initial radioactive iodine ablation therapy.
    Kim MH; O JH; Ko SH; Bae JS; Lim DJ; Kim SH; Baek KH; Lee JM; Kang MI; Cha BY; Lee KW
    Thyroid; 2012 Feb; 22(2):157-64. PubMed ID: 22224820
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Clinical value of different responses of serum thyroglobulin to recombinant human thyrotropin in the follow-up of patients with differentiated thyroid carcinoma.
    David A; Blotta A; Rossi R; Zatelli MC; Bondanelli M; Roti E; Braverman LE; Busutti L; degli Uberti EC
    Thyroid; 2005 Mar; 15(3):267-73. PubMed ID: 15785246
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Prediction of disease status by recombinant human TSH-stimulated serum Tg in the postsurgical follow-up of differentiated thyroid carcinoma.
    Pacini F; Molinaro E; Lippi F; Castagna MG; Agate L; Ceccarelli C; Taddei D; Elisei R; Capezzone M; Pinchera A
    J Clin Endocrinol Metab; 2001 Dec; 86(12):5686-90. PubMed ID: 11739420
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Clinical and pathological factors related to 18F-FDG-PET positivity in the diagnosis of recurrence and/or metastasis in patients with differentiated thyroid cancer.
    Esteva D; Muros MA; Llamas-Elvira JM; Jiménez Alonso J; Villar JM; López de la Torre M; Muros T
    Ann Surg Oncol; 2009 Jul; 16(7):2006-13. PubMed ID: 19415387
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Use of 18F FDG-PET in patients with suspicion of recurrent differentiated thyroid cancer by elevated antithyroglobulin antibodies levels and negative ¹³¹I scan].
    Sanz Viedma S; Borrego Dorado I; Rodríguez Rodríguez JR; Navarro González E; Vázquez Albertino R; Fernández López R; Agudo Martínez A
    Rev Esp Med Nucl; 2011; 30(2):77-82. PubMed ID: 21334773
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Serum thyroglobulin levels at the time of 131I remnant ablation just after thyroidectomy are useful for early prediction of clinical recurrence in low-risk patients with differentiated thyroid carcinoma.
    Kim TY; Kim WB; Kim ES; Ryu JS; Yeo JS; Kim SC; Hong SJ; Shong YK
    J Clin Endocrinol Metab; 2005 Mar; 90(3):1440-5. PubMed ID: 15613412
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Using recombinant human TSH in the management of well-differentiated thyroid cancer: current strategies and future directions.
    Mazzaferri EL; Kloos RT
    Thyroid; 2000 Sep; 10(9):767-78. PubMed ID: 11041454
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The diagnostic value for differentiated thyroid carcinoma metastases of thyroglobulin (Tg) measurement in washout fluid from fine-needle aspiration biopsy of neck lymph nodes is maintained in the presence of circulating anti-Tg antibodies.
    Boi F; Baghino G; Atzeni F; Lai ML; Faa G; Mariotti S
    J Clin Endocrinol Metab; 2006 Apr; 91(4):1364-9. PubMed ID: 16434461
    [TBL] [Abstract][Full Text] [Related]  

  • 51. US diagnosis of cervical recurrence in patients operated on thyroid cancer: sonographic features and clinical significance.
    Lee YH; Lee NJ; Kim JH; Song JJ
    Auris Nasus Larynx; 2007 Jun; 34(2):213-9. PubMed ID: 17270376
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Value of 18F-FDG PET negativity and Tg suppressibility as markers of prognosis in patients with elevated Tg and 131I-negative differentiated thyroid carcinoma (TENIS syndrome).
    Ranade R; Kand P; Basu S
    Nucl Med Commun; 2015 Oct; 36(10):1014-20. PubMed ID: 26049373
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Recombinant human thyrotropin in follow-up of patients with differentiated thyroid cancer.
    Podoba J
    Bratisl Lek Listy; 2010; 111(1):38-40. PubMed ID: 20429310
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Nuclear medicine approaches in the monitoring of thyroid cancer patients.
    Sergieva S; Hadjieva T; Doldurova M; Stefanova S; Dudov A
    J BUON; 2006; 11(4):511-8. PubMed ID: 17309186
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Persistent disease and recurrence in differentiated thyroid cancer patients with undetectable postoperative stimulated thyroglobulin level.
    Nascimento C; Borget I; Al Ghuzlan A; Deandreis D; Chami L; Travagli JP; Hartl D; Lumbroso J; Chougnet C; Lacroix L; Baudin E; Schlumberger M; Leboulleux S
    Endocr Relat Cancer; 2011 Apr; 18(2):R29-40. PubMed ID: 21183629
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The use of non-specific tracers in the follow up of differentiated thyroid cancer: results with Tc-99m tetrofosmin whole body scintigraphy.
    Lind P; Gallowitsch HJ
    Acta Med Austriaca; 1996; 23(1-2):69-75. PubMed ID: 8767519
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Quantitative reverse transcription-polymerase chain reaction of circulating thyroglobulin messenger ribonucleic acid for monitoring patients with thyroid carcinoma.
    Ringel MD; Balducci-Silano PL; Anderson JS; Spencer CA; Silverman J; Sparling YH; Francis GL; Burman KD; Wartofsky L; Ladenson PW; Levine MA; Tuttle RM
    J Clin Endocrinol Metab; 1999 Nov; 84(11):4037-42. PubMed ID: 10566646
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Prognostic factors affecting disease-specific survival in patients with recurrent and/or metastatic differentiated thyroid carcinoma detected by positron emission tomography/computed tomography.
    Akkas BE; Demirel BB; Vural GU
    Thyroid; 2014 Feb; 24(2):287-95. PubMed ID: 23750862
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Thyroglobulin detection in fine-needle aspirates of cervical lymph nodes: a technique for the diagnosis of metastatic differentiated thyroid cancer.
    Cunha N; Rodrigues F; Curado F; Ilhéu O; Cruz C; Naidenov P; Rascão MJ; Ganho J; Gomes I; Pereira H; Real O; Figueiredo P; Campos B; Valido F
    Eur J Endocrinol; 2007 Jul; 157(1):101-7. PubMed ID: 17609408
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Thyroglobulin measurement in fine-needle aspirates of lymph nodes in patients with differentiated thyroid cancer: a simple definition of the threshold value, with emphasis on potential pitfalls of the method.
    Bournaud C; Charrié A; Nozières C; Chikh K; Lapras V; Denier ML; Paulin C; Decaussin-Petrucci M; Peix JL; Lifante JC; Cornu C; Giraud C; Orgiazzi J; Borson-Chazot F
    Clin Chem Lab Med; 2010 Aug; 48(8):1171-7. PubMed ID: 20441483
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.